PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Patients with age ≥ 18 years

• diagnosis of lymphoma(Hodgkin's lymphoma and non-Hodgkin's lymphoma) patients

• Karnofsky Performance Status Z70

• life expectancy of at least 8 months

• normal white blood cell count and platelet count

• Written informed consent are acquired

Exclusion Criteria:

• uncontrolled infection

• pregnancy

• Have accepted any other anti-tumor drug within 4 weeks before anticipated the study

• Other situations that investigators consider as contra-indication for this study